Eli Lilly and Company (LLY) Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 1:30 PM EDT
Company Participants
Daniel Skovronsky – Chief Scientific & Product Officer and President of Lilly Research Laboratories
Conference Call Participants
Courtney Breen – Bernstein Institutional Services LLC, Research Division
Presentation
Courtney Breen
Bernstein Institutional Services LLC, Research Division
Hi, everyone. Thank you so much for being with us today. It is my pleasure to be sharing the stage with Dan Skovronsky, Chief Scientific Officer as well as Chief Product Officer at Eli Lilly. We will be having hopefully an insightful conversation on the company and particularly given his role, kind of the approach to R&D at Lilly and how that continues to evolve.
Question-and-Answer Session
Courtney Breen
Bernstein Institutional Services LLC, Research Division
While I have a long list of questions that I’m really excited to ask Dan, I also recognize that there’s a bunch of people in this room that also have questions that might differ from mine. So we do have the Pigeonhole app. Please feel free to add any questions that you have of interest into that app, and I’ll do my best to work them into the conversation. So please dive into that so that we get kind of the most robust conversation that we can today. So with that, I want to start with a little bit of scene setting perhaps.
Daniel Skovronsky
Chief Scientific & Product Officer and President of Lilly Research Laboratories
Sure.
Courtney Breen
Bernstein Institutional Services LLC, Research Division
Eli Lilly is and has just had its 150th birthday, a relatively old company, and it’s certainly been around for a while. It has become a relative household name though in recent times, kind of now with the GLP-1s and certainly even with a broader base of investors as
